抑郁症、衰老与免疫：对新冠疫苗免疫原性的影响。
Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity.
作者信息
Ford Bart N, Savitz Jonathan
机构信息
Department of Pharmacology & Physiology, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA.
Laureate Institute for Brain Research, Tulsa, OK, USA.
出版信息
Immun Ageing. 2022 Jul 14;19(1):32. doi: 10.1186/s12979-022-00288-7.
Abstract
The aging process can have detrimental effects on the immune system rendering the elderly more susceptible to infectious disease and less responsive to vaccination. Major depressive disorder (MDD) has been hypothesized to show characteristics of accelerated biological aging. This raises the possibility that depressed individuals will show some overlap with elderly populations with respect to their immune response to infection and vaccination. Here we provide an umbrella review of this literature in the context of the SARS CoV-2 pandemic. On balance, the available data do indeed suggest that depression is a risk factor for both adverse outcomes following COVID-19 infection and for reduced COVID-19 vaccine immunogenicity. We conclude that MDD (and other major psychiatric disorders) should be recognized as vulnerable populations that receive priority for vaccination along with other at-risk groups.
摘要
衰老过程会对免疫系统产生不利影响，使老年人更容易感染传染病，且对疫苗接种的反应性降低。据推测，重度抑郁症（MDD）具有加速生物衰老的特征。这增加了一种可能性，即抑郁症患者在对感染和疫苗接种的免疫反应方面，会与老年人群体存在一些重叠。在此，我们在新冠病毒大流行的背景下，对这一文献进行综合综述。总体而言，现有数据确实表明，抑郁症是新冠病毒感染后出现不良后果以及新冠疫苗免疫原性降低的一个风险因素。我们得出结论，重度抑郁症（以及其他主要精神疾病）应被视为弱势群体，与其他高危群体一起优先接种疫苗。
相似文献
1
Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity.抑郁症、衰老与免疫：对新冠疫苗免疫原性的影响。
Immun Ageing. 2022 Jul 14;19(1):32. doi: 10.1186/s12979-022-00288-7.
2
Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.免疫反应随衰老而重塑：免疫衰老及其对 COVID-19 免疫反应的潜在影响。
Front Immunol. 2020 Aug 7;11:1748. doi: 10.3389/fimmu.2020.01748. eCollection 2020.
3
Immunosenescence, Inflammaging and Resilience: An Evolutionary Perspective of Adaptation in the Light of COVID-19 Pandemic.免疫衰老、炎症衰老与韧性：COVID-19 大流行背景下适应的进化视角。
Psychiatr Danub. 2021 Spring-Summer;33(Suppl 4):427-431.
4
Aging, inflammaging and immunosenescence as risk factors of severe COVID-19.衰老、炎症衰老和免疫衰老作为重症 COVID-19 的风险因素。
Immun Ageing. 2022 Nov 11;19(1):53. doi: 10.1186/s12979-022-00309-5.
5
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
6
Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity.衰老与免疫系统：免疫衰老对病毒感染、免疫及疫苗免疫原性的影响。
Immune Netw. 2019 Nov 14;19(6):e37. doi: 10.4110/in.2019.19.e37. eCollection 2019 Dec.
7
Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak.同种异体 priming 作为一种通用抗病毒疫苗：保护老年人免受当前 COVID-19 和任何未来未知的病毒爆发的影响。
J Transl Med. 2020 May 12;18(1):196. doi: 10.1186/s12967-020-02363-3.
8
Immunosenescence and inflammaging in the aging process: age-related diseases or longevity?免疫衰老与衰老过程中的炎症：与年龄相关的疾病还是长寿？
Ageing Res Rev. 2021 Nov;71:101422. doi: 10.1016/j.arr.2021.101422. Epub 2021 Aug 13.
9
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].不同 COVID-19 疫苗组合在健康个体中的安全性和免疫原性评估：一项随机、设盲、对照的 3 期临床试验 [PRIBIVAC] 的研究方案。
Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2.
10
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
引用本文的文献
1
Gene age gap estimate (GAGE) for major depressive disorder: A penalized biological age model using gene expression.重度抑郁症的基因年龄差距估计（GAGE）：一种使用基因表达的惩罚性生物学年龄模型。
Neurobiol Aging. 2025 Jul;151:13-21. doi: 10.1016/j.neurobiolaging.2025.01.012. Epub 2025 Apr 1.
2
Gene Age Gap Estimate (GAGE) for major depressive disorder: a penalized biological age model using gene expression.重度抑郁症的基因年龄差距估计（GAGE）：一种使用基因表达的惩罚性生物学年龄模型。
bioRxiv. 2024 Nov 17:2024.09.03.610913. doi: 10.1101/2024.09.03.610913.
3
Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan.新型冠状病毒肺炎mRNA初次和加强疫苗接种后长期护理机构居民中促炎和抗炎刺突特异性细胞免疫反应的动力学：日本一项前瞻性纵向研究
Immun Ageing. 2024 Jun 22;21(1):41. doi: 10.1186/s12979-024-00444-1.
4
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.序贯接种新冠灭活疫苗和重组蛋白疫苗对老年人的安全性、免疫原性和保护效果：一项前瞻性纵向研究。
Signal Transduct Target Ther. 2024 May 13;9(1):129. doi: 10.1038/s41392-024-01846-9.
5
Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease.免疫衰老与巨细胞病毒：在衰老、健康和疾病背景下探索它们的关联。
Int J Mol Sci. 2024 Jan 6;25(2):753. doi: 10.3390/ijms25020753.
6
Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan.长期护理机构居民中COVID-19 mRNA 初免和加强疫苗对关注的SARS-CoV-2变异株的中和活性动力学：日本的一项前瞻性纵向研究
Immun Ageing. 2023 Aug 17;20(1):42. doi: 10.1186/s12979-023-00368-2.
7
Aged brain and neuroimmune responses to COVID-19: post-acute sequelae and modulatory effects of behavioral and nutritional interventions.衰老大脑与对新冠病毒的神经免疫反应：急性后遗症以及行为和营养干预的调节作用
Immun Ageing. 2023 Apr 12;20(1):17. doi: 10.1186/s12979-023-00341-z.
本文引用的文献
1
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.保护和衰减对 SARS-CoV-2 的天然和混合免疫。
N Engl J Med. 2022 Jun 9;386(23):2201-2212. doi: 10.1056/NEJMoa2118946. Epub 2022 May 25.
2
Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults.接种疫苗的成年人中精神疾病与SARS-CoV-2突破性感染发生率的关联
JAMA Netw Open. 2022 Apr 1;5(4):e227287. doi: 10.1001/jamanetworkopen.2022.7287.
3
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.具有自然免疫和混合免疫的个体中再次感染SARS-CoV-2和因COVID-19住院的风险：瑞典一项回顾性全人群队列研究
Lancet Infect Dis. 2022 Jun;22(6):781-790. doi: 10.1016/S1473-3099(22)00143-8. Epub 2022 Apr 1.
4
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).广泛免疫抑制人群中新型冠状病毒病 2019（COVID-19）疫苗反应的前瞻性评估：免疫抑制人群中的 COVID-19 疫苗接种研究（COVICS）。
Clin Infect Dis. 2022 Aug 24;75(1):e630-e644. doi: 10.1093/cid/ciac103.
5
Population antibody responses following COVID-19 vaccination in 212,102 individuals.212102 例个体接种 COVID-19 疫苗后的人群抗体反应。
Nat Commun. 2022 Feb 16;13(1):907. doi: 10.1038/s41467-022-28527-x.
6
Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis.新冠病毒病后的持续性神经精神症状：一项系统综述和荟萃分析
Brain Commun. 2021 Dec 17;4(1):fcab297. doi: 10.1093/braincomms/fcab297. eCollection 2022.
7
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.单剂 Ad26.COV2.S 疫苗的疗效和安全性的最终分析
N Engl J Med. 2022 Mar 3;386(9):847-860. doi: 10.1056/NEJMoa2117608. Epub 2022 Feb 9.
8
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.炎症性肠病（IBD）免疫抑制患者 COVID-19 疫苗诱导的抗体反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-352. doi: 10.1016/S2468-1253(22)00005-X. Epub 2022 Feb 4.
9
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.接种疫苗后癌症患者对 SARS-CoV-2 关切变异株的适应性免疫和中和抗体：CAPTURE 研究。
Nat Cancer. 2021 Dec;2(12):1305-1320. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.
10
T cell responses to SARS-CoV-2 spike cross-recognize Omicron.T 细胞对 SARS-CoV-2 刺突蛋白的交叉识别可识别奥密克戎。
Nature. 2022 Mar;603(7901):488-492. doi: 10.1038/s41586-022-04460-3. Epub 2022 Jan 31.
Zotero 插件